Financial targets

Immunovia Targeting Long-Term Market Penetration of 30% for IMMray™ PanCan-d after reimbursement and widespread insurance coverage is achieved (link PR 30 June 2020)

Immunovia’s first to market product IMMray™ PanCan-d, is a long-sought solution for the unmet need of early and accurate detection of pancreatic cancer (PDAC).
Sales start for IMMray™ PanCan-d in the United States is planned for Q1 2021 with subsequent commercial testing Q2 2021.

There are more than 7 million eligible patients annually and no existing accurate diagnostics option on the market. Immunovia targets a long-term market penetration of 30% after reimbursement and widespread coverage. The current size of the addressable market for IMMray™ PanCan-d is estimated to exceed USD 4 billion in EU and United States, across the three risk groups that the company targets: Hereditary/Familial, Early Symptoms and Newly Onset Diabetes after 50 years of age.

Guided by Pancreatic ductal adenocarcinoma (PDAC) Key Opinion Leaders, Immunovia’s IMMray™ PanCan-d targets these well-defined high-risk groups as well as bottlenecks in current healthcare processes, by providing differential diagnosis in the detection of PDAC. This will result in patients and the healthcare systems reaping maximum benefits. Additionally, this supports one of Immunovia’s main objectives which is to have IMMray™ PanCan-d be included in respective countries’ National Guidelines.

Immunovia’s financial targets set forth above constitute forward-looking information and are based on a number of assumptions about the environment in which the Company operates, which may vary significantly and deteriorate over time from what Immunovia assessed when the financial targets were adopted. As a consequence, Immunovia’s ability to achieve the financial targets consists of uncertainties and contingencies, some of which are outside the Company’s control. There is no guarantee that Immunovia can achieve the financial targets or that Immunovia’s financial position or operating profit will not differ materially from the financial targets.


Subscribe to receive press releases and reports via email
To start your subscription you need to activate your e-mail address by clicking the link in the email that is sent to you after you have submitted this form. Please check the junk mail if you cannot find the message.

Press releases
Financial reports